Liu Huang: Clinical Trials

2 recruiting, 1 not yet recruiting. 3 Phase 2, 1 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	3	Recruiting 2, Not yet recruiting 1
Phase 1	1	Recruiting 1

Follow Liu Huang: new trials by email

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer Fruquintinib+Irinotecan Liposome+Capecitabine, Bevacizumab+Irinotecan Liposome+Capecitabine - Colorectal Cancer (CRC)	Phase 2	Not yet recruiting	Liu Huang	68	2025-07-07	2025-07-04
Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer Glumetinib Combined with Fruquintinib - Metastatic Colorectal Cancer	Phase 1 / Phase 2	Recruiting	Liu Huang	42	2025-04-25	2025-05-20
Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer Paclitaxel Polymeric Micelles for Injection - Pancreatic Adenocarcinoma, Cholangiocarcinoma	Phase 2	Recruiting	Liu Huang	25	2023-11-28	2025-06-03

Conditions studied

Colorectal Neoplasms (2)  ·  Breast Neoplasms (1)  ·  Cholangiocarcinoma (1)  ·  Esophageal Neoplasms (1)  ·  Lung Neoplasms (1)  ·  Stomach Neoplasms (1)

Interventions

HMPL-013 (1)  ·  Injections (1)

Countries

China (2)

Top investigators

Xianglin Yuan (1)